Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial

4 November 2022 – FDA published final guidance for studies that evaluate multiple versions of a cellular or gene therapy product.

The purpose of this guidance is to provide recommendations to sponsors interested in studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial for a single disease.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /